<DOC>
	<DOCNO>NCT01517243</DOCNO>
	<brief_summary>In past 5 year , treatment metastatic Renal Cell Carcinoma ( mRCC ) focus agent direct block tumor vascular growth pathway . Sunitinib block vascular endothelial growth factor receptor ( VEGFr ) temsirolimus inhibitor mammalian target rapamycin ( mTOR ) . Both sunitinib temsirolimus FDA approve agent mRCC . When agent like give together , toxicity increase give safely , full dos , sequentially . We hypothesize alternate agent double progression free survival ( PFS ) agent give sequentially .</brief_summary>
	<brief_title>Phase II Study Alternating Sunitinib Temsirolimus</brief_title>
	<detailed_description>SUMMARY : Alternating Targeted Therapy Patients Metastatic Renal Cell Carcinoma : A Phase II Study Alternating Sunitinib Temsirolimus Patients measurable metastatic renal cell carcinoma ( histology ) eligible . All patient treat outlined sunitinib alternate temsirolimus . Patients treat continuously , evidence progression disease , two cycle follow disappearance disease . A cycle define : Sunitinib 50mg mouth daily 4 week follow two week rest Temsirolimus 25mg IV weekly 4 week follow two week rest</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion Criteria Histologically confirm metastatic renal cell cancer evaluable disease . Patients must least 2 week last immunotherapy , surgery chemotherapy ( 6 week nitrosureas ) recover ill effect . Karnofsky Performance Status ≥60 % Life expectancy ≥ twelve week Adequate end organ function : Cardiac Left ventricular ejection fraction ( LVEF ) ≥lower limit institutional normal ( LLN ) assess echocardiography ( ECHO ) . The modality use baseline must apply subsequent evaluation . Women lactate , childbearing age , negative pregnancy test within two week entry study practice acceptable form birth control Appropriate Contraception sex The patient must competent sign informed consent . EXCLUSION CRITERIA Concomitant second malignancy except nonmelanoma skin cancer , noninvasive cancer cervical CIS , superficial bladder cancer without local recurrence , breast CIS . In patient prior history invasive malignancy , less five year complete remission . Have evidence significant comorbid illness uncontrolled diabetes , hypertension active infection would preclude treatment regimen . Prior treatment either sunitinib temsirolimus Clinically significant gastrointestinal abnormality Presence uncontrolled infection . Prolongation correct QT interval ( QTc ) &gt; 480 millisecond History one follow cardiovascular condition within past 12 month : 1 . Cardiac angioplasty stenting 2 . Myocardial infarction 3 . Unstable angina 4 . Coronary artery bypass graft surgery 5 . Symptomatic peripheral vascular disease 6 . Class III IV congestive heart failure , define New York Heart Association ( NYHA ) History cerebrovascular accident ( CVA ) include transient ischemic attack ( TIA ) within past 12 month . History pulmonary embolism untreated deep venous thrombosis ( DVT ) within past 6 month . Note : Subjects recent DVT treat therapeutic anticoagulating agent least 6 week eligible . Poorly control hypertension [ define systolic blood pressure ( SBP ) ≥150 diastolic blood pressure ( DBP ) ≥ 90 . Note : Initiation adjustment antihypertensive medication ( ) permit prior study entry . Prior major surgery trauma within 28 day prior first dose study drug and/or presence nonhealing wound , fracture , ulcer . Evidence active bleeding bleed diathesis Hemoptysis within 6 week first dose study drug . Known endobronchial lesion and/or lesion infiltrate major pulmonary vessel Any serious and/or unstable preexist medical , psychiatric , condition could interfere subject 's safety , obtain informed consent compliance study . Is undergo and/or undergone 14 day immediately prior first dose study drug minor surgery ( i.e . skin biopsy , tooth extraction , etc . ) recover ill effect . Any ongoing toxicity prior anticancer therapy &gt; Grade 1 and/or progress severity . Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate sunitinib temsirolimus . Untreated brain metastasis . ( Brain metastases stable base radiographic evidence 4 week radiation and/or surgery permit ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Metastatic Renal Cell Carcinoma</keyword>
	<keyword>sunitinib</keyword>
	<keyword>alternate</keyword>
	<keyword>temsirolimus</keyword>
</DOC>